Capsensixx AG (FRA:CPX) Research & Development: €0.0 Mil (TTM As of Dec. 2025)


FRA:CPX Capsensixx AG FRA:CPX
87 GF Score
Price €21.40
GF Value €27.46
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Capsensixx AG Research & Development?

Capsensixx AG FRA:CPX 87 Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus rates FRA:CPX with a GF Score™ of 87/100 and a GF Value™ of €27.46 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Capsensixx AG's Research & Development for the six months ended in Dec. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Capsensixx AG  (FRA:CPX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Capsensixx AG Research & Development Related Terms

Capsensixx AG Research & Development Historical Data

* Premium members only.

The historical data trend for Capsensixx AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capsensixx AG Research & Development Chart

Capsensixx AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Capsensixx AG Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:CPX
87GF Score
Capsensixx AG FRA:CPX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Capsensixx AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Capsensixx AG (FRA:CPX) has a Research & Development of €0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Capsensixx AG and its competitors.
Is Capsensixx AG's Research & Development too high?
Capsensixx AG's current Research & Development is €0.0 Mil. Overall, Capsensixx AG has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Capsensixx AG's Research & Development compare to BLK and BX?
Capsensixx AG's Research & Development of €0.0 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Asset Management company?
A good Research & Development depends on the Asset Management industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Capsensixx AG and its competitors. Capsensixx AG's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capsensixx AG stock overvalued right now?
Based on GuruFocus' analysis, Capsensixx AG (FRA:CPX) is currently considered Modestly Undervalued. The stock's GF Value™ is €27.46, compared to a current price of €21.40 — trading 22.1% below its estimated fair value. The current Research & Development is €0.0 Mil. Capsensixx AG's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Capsensixx AG (FRA:CPX), the current Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Capsensixx AG (FRA:CPX) Overvalued in 2026?

Based on GuruFocus' analysis, Capsensixx AG stock appears to be undervalued. The current stock price of €21.40 is trading 22.1% below its estimated GF Value™ of €27.46. GuruFocus considers Capsensixx AG to be Modestly Undervalued.

Key valuation signals for FRA:CPX:

  • Research & Development: €0.0 Mil
  • GF Value™: €27.46 vs. price of €21.40 (22.1% below fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the FRA:CPX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Capsensixx AG Business Description

Other Exchanges CPX:Germany
Address Bettinastrasse 57-59, Frankfurt, DEU, D-60325
Capsensixx AG is a provider of financial administration as a service. The company is divided into two segments namely Funds management, Administration and Accounting Segment which includes fund management and fund accounting; and Securitisations which provides Advisory services in the field of financial engineering, securitisation and provision of director and administrative services to corporate clients in Luxembourg.
87GF Score

Get the complete analysis for FRA:CPX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.40
Price
€27.46
GF Value